Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.
相关临床试验
6
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2014
进行中（未招募）
1
16.7%
已完成
2
33.3%
尚未招募
1
16.7%
招募中
2
33.3%
暂无批准数据
- The checkpoint inhibitor refractory cancer market is expected to grow significantly by 2036, driven by rising resistance to immune checkpoint inhibitors and demand for next-generation therapies. - Approximately 40–60% of patients with melanoma, NSCLC, renal cell carcinoma, urothelial carcinoma, and head and neck cancers experience primary resistance to PD-1/PD-L1 inhibitor therapy. - Promising investigational therapies include Sitravatinib + Nivolumab, TAVO + Pembrolizumab, Botensilimab + Balstilimab, and ICT01, which aim to overcome resistance and restore antitumor immunity. - The United States accounted for the largest checkpoint inhibitor refractory cancer treatment market size in the 7MM in 2025.
- Johnson & Johnson's ECHO study demonstrates that Spravato (esketamine nasal spray) maintains antidepressant effects for six months after patients discontinue treatment, with most patients showing no signs of relapse. - The Phase IV real-world study of 570 patients with severe treatment-resistant depression showed significant MADRS score improvements of 14.4 points at 12 weeks and 17.6 points at 48 weeks of treatment. - The study represents the largest European real-world dataset for esketamine and provides the first evidence of treatment durability after discontinuation in clinical practice settings. - Spravato's success may pave the way for other psychedelic therapies in development, as clinics administering the drug already have infrastructure for supervised psychoactive treatments.
- Compass Therapeutics appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, both effective January 1, 2026. - Prasad brings extensive commercial experience including over 10 successful oncology launches, notably the blockbuster VORANIGO launch in 2024 and TIBSOVO for biliary tract cancer patients. - Sirard contributes more than two decades of oncology drug development expertise, having guided multiple programs through clinical development, pivotal trials, and regulatory approval. - The appointments strengthen Compass's execution capabilities as the company advances tovecimig and its broader immuno-oncology pipeline toward potential commercialization.
- Compass Therapeutics reports confirmed third response with CTX-8371 in Hodgkin lymphoma patient, expanding therapeutic potential beyond solid tumors to hematologic malignancies. - The company's tovecimig Phase 2/3 COMPANION-002 study in biliary tract cancer remains on track for key survival data in late Q1 2026, following successful primary endpoint achievement. - CTX-8371 cohort expansions are now enrolling patients with triple-negative breast cancer and non-small cell lung cancer based on durable responses observed in Phase 1 studies. - The company strengthened leadership with new Chief Commercial Officer and Chief Medical Officer appointments, while maintaining $209 million cash runway through 2028.
- H.C. Wainwright reiterated positive outlook on Compass Therapeutics following encouraging preclinical progress for CTX-10726 and favorable initial results for CTX-8371 in the company's oncology pipeline. - The company expects pivotal survival data for tovecimig in late Q1 2026, which could support its first biologics license application filing in the second half of next year. - Recent analyst optimism contributed to a 17.2% share price increase, though the company remains unprofitable with increasing operating losses.
- Compass Therapeutics' tovecimig met its primary endpoint in Phase 2/3 biliary tract cancer trial, with fewer deaths observed than projected suggesting potential overall survival benefit. - CTX-8371 bispecific antibody demonstrated deep responses in post-checkpoint inhibitor setting, including complete resolution of lung cancer lesions and >90% reduction in breast cancer tumors. - CTX-10726 showed superior tumor control and PD-1 inhibition compared to ivonescimab in preclinical studies, with IND filing planned for Q4 2025. - The company maintains strong financial position with $101 million in cash providing runway into 2027.
- Compass Therapeutics received FDA Fast Track Designation for CTX-009, its bispecific DLL4/VEGF-A antibody, when used in combination with other treatments. - The designation indicates FDA recognition of CTX-009's potential to address unmet medical needs and commitment to supporting its development. - CMPX shares surged 4.01% on the news, marking the third consecutive day of gains with a cumulative increase of 7.95% over three days. - The Fast Track Designation is expected to expedite the development and approval process while potentially attracting increased investor attention and collaboration opportunities.
- Commit Biologics has established a Scientific Advisory Board co-chaired by antibody expert Janine Schuurman and CEO Mikkel Wandahl Pedersen to guide development of its BiCE™ complement activation platform. - The board includes five industry veterans with expertise in molecular biology, immunology, and antibody research, including former executives from Genmab, Regeneron, and Novo Nordisk. - The BiCE™ technology platform aims to harness the largely untapped complement system to selectively kill target cells in autoimmune diseases and cancer through enhanced C1q engagement. - This strategic move positions Commit to accelerate development of first-in-class complement engager therapeutics by leveraging decades of combined industry experience from the advisory members.
- Compass Therapeutics is set to release Phase 2/3 data for tovecimig in biliary tract cancer by the end of Q1 2025, marking a key milestone. - A novel PD-1 x VEGF-A bispecific antibody, CTX-10726, is advancing as a new drug candidate, with an IND submission expected by year-end 2025. - Two Phase 2 biomarker trials are planned for mid-2025, evaluating tovecimig in DLL4-positive colorectal cancer and CTX-471 in NCAM/CD56 expressing tumors. - Compass Therapeutics reports a strong financial position with an estimated $127 million in cash, providing a runway into Q1 2027 for continued development.
• Compass Therapeutics presented data at SITC showing a significant correlation between NCAM expression and patient response to CTX-471 monotherapy. • The Phase 1 trial data suggests NCAM enriches activated NK cells in the tumor microenvironment, potentially enhancing CTX-471's efficacy. • A Phase 2 monotherapy basket study is planned to further evaluate CTX-471 in patients with NCAM-expressing tumors who have progressed on PD-1/PD-L1 inhibitors. • The findings support the potential use of NCAM as a predictive biomarker for patient selection in future CTX-471 clinical trials.
